Premium
Tadalafil: A Phosphodiesterase‐5 Inhibitor for Benign Prostatic Hyperplasia
Author(s) -
Cantrell Matthew A.,
Baye Jordan,
Vouri Scott Martin
Publication year - 2013
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.1243
Subject(s) - tadalafil , medicine , concomitant , erectile dysfunction , placebo , adverse effect , cgmp specific phosphodiesterase type 5 , hyperplasia , lower urinary tract symptoms , urology , drug , pharmacology , prostate , pathology , alternative medicine , cancer
Tadalafil is a phosphodisesterase ( PDE )‐5 inhibitor recently approved by the United States Food and Drug Administration for lower urinary tracts symptoms ( LUTS ) associated with benign prostatic hyperplasia ( BPH ). The mechanism for improved LUTS is thought to be related to three principal theories: alterations in nitric oxide levels, Rho‐associated protein kinase deactivation, and reductions in pelvic atherosclerosis. The efficacy of PDE ‐5 inhibitors for the treatment of LUTS associated with BPH has been demonstrated in several randomized placebo‐controlled trials. Tadalafil is thought to be superior based on an extended half‐life; however, other PDE ‐5 inhibitors have positive results in BPH and have not been proved to be inferior to tadalafil. Before administration, concomitant use of medications such as nonselective α‐adrenergic antagonists, nitrates, and cytochrome P 450 inhibitors should be assessed for possible drug interactions. Potential adverse drug events seen in Food and Drug Administration –approved tadalafil include back pain, dyspepsia, headache, and dizziness. Given the efficacy and safety data currently available, the PDE ‐5 inhibitor tadalafil represents a reasonable alternative for selected male patients with LUTS associated with BPH , especially with concomitant erectile dysfunction.